Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 131-139 , April 2010

Human immunodeficiency and Hodgkin lymphoma

  • Gerhard Sissolak

      Affiliations

    • Division of Clinical Haematology, Department of Internal Medicine, Faculty of Health Sciences, Stellenbosch University, Tygerberg Academic Hospital, South Africa
    • ,
  • Dagmar Sissolak

      Affiliations

    • Division of Clinical Haematology, Department of Internal Medicine, Faculty of Health Sciences, Stellenbosch University, Tygerberg Academic Hospital, South Africa
    • ,
  • Peter Jacobs

      Affiliations

    • Division of Clinical Haematology, Department of Internal Medicine, Faculty of Health Sciences, Stellenbosch University, Tygerberg Academic Hospital, South Africa
    • University of Cape Town, South Africa
    • College of Medicine, University of Nebraska Medical Centre, South Africa
    • The Department of Haematology and Bone Marrow Transplant Unit, Incorporating The Searll Research Laboratory for Cellular and Molecular Biology, Constantiaberg Medi-Clinic, Burnham Road, Plumstead, Cape Town, South Africa
    • Corresponding Author InformationCorresponding author. Address: Constantiaberg Medi-Clinic, P.O. Box 294, Plumstead 7800, Cape Town, South Africa. Tel.: +27 21 799 2566; fax: +27 21 761 4278.

References 

  1. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305:1425–1431
  2. Harris C, Small CB, Klein RS, Friedland GH, Moll B, Emeson EE, et al. Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med. 1983;308:1181–1184
  3. Stebbing J, Bower M. What can oncologists learn from HIV?. Lancet Oncol. 2003;4:438–445
  4. Ziegler JL, Templeton AC, Vogel CL. Kaposi’s sarcoma: a comparison of classical, endemic, and epidemic forms. Semin Oncol. 1984;11:47–52
  5. Boring CC, Brynes RK, Chan WC, Causey N, Gregory HR, Nadel MR, et al. Increase in high-grade lymphomas in young men. Lancet. 1985;1:857–859
  6. Levine AM, Gill PS, Meyer PR, Burkes RL, Ross R, Dworsky RD, et al. Retrovirus and malignant lymphoma in homosexual men. JAMA. 1985;254:1921–1925
  7. Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin’s lymphoma. Cancer Treat Rev. 2004;30:249–253
  8. Thirlwell C, Sarker D, Stebbing J, Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma. 2003;4:86–92
  9. Phelps RM, Smith DK, Heilig CM, Gardner LI, Carpenter CC, Klein RS, et al. Cancer incidence in women with or at risk for HIV. Int J Cancer. 2001;94:753–757
  10. Goedert JJ, Coté TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833–1839
  11. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 2003;4:110–119
  12. Powles T, Bower M, Daugaard G, Shamash J, de Ruiter A, Johnson M, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol. 2003;21:1922–1927
  13. International Agency for Research on Cancer (IARC). Human immunodeficiency viruses and human T-cell lymphotropic viruses. Lyon: IARC, 1996:261-390. (monographs on the evaluation of carcinogenic risks to humans; Vol. 67).
  14. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–194
  15. Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, et al. Hodgkin lymphoma in the Swiss cohort study. Blood. 2009;113:5737–5742
  16. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113:1213–1224
  17. UNAIDS. Report on the global AIDS epidemic. Geneva: UNAIDS; 2006.
  18. National HIV and syphilis sero-prevalence survey of women attending public health antenatal clinics in South Africa. Pretoria: Department of Health; 2005. <http://www.doh.gov.za/docs/reports/2005/hiv.pdf>.
  19. Thomas JO. Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa. Semin Oncol. 2001;28:198–206
  20. Sissolak G, Mayaud P. AIDS related Kaposi’s sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health. 2005;10:981–992
  21. Sissolak G, Abayomi A, Jacobs P. AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART)–an African perspective. Transfus Apher Sci. 2007;37:63–70
  22. Hessol NA, Katz MH, Liu JY, Buchbinder SP, Rubino CJ, Holmberg SD. Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med. 1992;117:309–311
  23. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin’s lymphoma. Haematologica. 2005;90:1680–1692
  24. Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. Cancer. 2003;98:300–309
  25. Shisana O, Rehle T, Simbayi L, Parker W, Zuma K, Bhana A, et al. South African national HIV prevalence, HIV incidence, behaviour and communications survey. Cape Town: Human Sciences Research Council; 2005;
  26. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–432
  27. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20:1645–1654
  28. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786–3791
  29. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16:1155–1161
  30. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spoone K, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104:1505–1511
  31. International Agency for Research on Cancer (IARC). Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. Lyon: IARC; 1997 [Monographs on the evaluation of carcinogenic risks to humans; Vol. 70].
  32. Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin’s disease. Eur J Cancer. 2001;37:1276–1287
  33. Boiocchi M, De Re V, Gloghini A, Vaccher E, Dolcetti R, Marzotto A, et al. High incidence of monoclonal EBV episomes in Hodgkin’s disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients. Int J Cancer. 1993;54:53–59
  34. Spina M, Berretta M, Tirelli U. Hodgkin’s disease in HIV. Hematol Oncol Clin North Am. 2003;17:843–858
  35. Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375–382
  36. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr. 2002;31:536–541
  37. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–1510
  38. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin’s disease and other tumours in HIV-infected individuals. Eur J Cancer. 2001;37:1306–1315
  39. Levine AM. Hodgkin’s disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr. 1998;23:37–42
  40. Andrieu JM, Roithmann S, Tourani JM, Levy R, Desablens B, le Maignan C, et al. Hodgkin’s disease during HIV1 infection: the French registry experience. French registry of HIV-associated tumors. Ann Oncol. 1993;4:635–641
  41. Poluri A, Shah KG, Carew JF, Shaha AR, Har-El G, Lucente FE, et al. Hodgkin’s disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol. 2002;23:12–16
  42. Diehl V. Hodgkin’s disease–from pathology specimen to cure. N Engl J Med. 2007;357:1968–1971
  43. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–59
  44. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno T, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–481
  45. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early Interim 2-[18F]Fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol. 2007;25:3746–3752
  46. Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol. 2007;25:3902–3907
  47. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22:2835–2841
  48. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25:3495–3502
  49. Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol. 2005;23:6400–6408
  50. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–614
  51. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484
  52. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: national cancer institute of Canada clinical trials group and the eastern cooperative oncology group. J Clin Oncol. 2005;23:4634–4642
  53. Evens AM, Cilley J, Ortiz T, Gounder M, Houn N, Rademaker A, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137:545–552
  54. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–7620
  55. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630–637
  56. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP–ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–2395
  57. Hasenclever D, Diehl V, Armitage JO, Assouline D, Björkholm M, Brusamolino E, et al. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–1514
  58. Wedgwood AR, Fanale MA, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, et al. Rituximab+ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2–3 cycles of therapy. Blood 2007;110:71a [abstract 215].
  59. Jones RJ, Lin L, Gocke C, Hensley K, Siedner M, Barber JP, et al. Clonotypic B cells circulate in Hodgkin’s lymphoma (HL). Blood 2006;108:143a [Abstract 470].
  60. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–218
  61. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:528–534
  62. Roach M, Brophy N, Cox R, Varghese A, Hoppe RT. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease. J Clin Oncol. 1990;8:623–629
  63. Mauch P, Tarbell N, Skarin A, Rosenthal D, Weinstein H. Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol. 1987;5:544–549
  64. Roach M, Kapp DS, Rosenberg SA, Hoppe RT. Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol. 1987;5:550–555
  65. Lohri A, Barnett M, Fairey RN, O’Reilly SE, Phillips GL, Reece D, et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77:2292–2298
  66. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood. 1997;89:814–822
  67. Kuruvilla J, Song K, Mollee P, Panzarella T, McCrae J, Nagy T, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin’s lymphoma. Hematology. 2006;11:25–29
  68. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109–111
  69. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–1054
  70. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–633
  71. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124:645–652
  72. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071–1079
  73. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106:353–360
  74. Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, et al. A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European organization for research and treatment of cancer lymphoma cooperative group and groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994;12:279–287
  75. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International database on Hodgkin’s disease overview study group. J Clin Oncol. 1998;16:818–829
  76. Fermé C, Sebban C, Hennequin C, Diviné M, Lederlin P, Gabarre J, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 trial. Blood. 2000;95:2246–2252
  77. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease: eastern cooperative oncology group pilot study E1492. J Clin Oncol. 2000;18:972–980
  78. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol. 1996;6:225–242
  79. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435–2443
  80. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487–497
  81. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–3494
  82. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–3439
  83. van Leeuwen FE, Swerdlow AJ, Valagussa P, Tucker MA. Second cancers after treatment of Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin’s disease. Philadelphia: Lippincott Williams and Wilkins; 1999: 607–32.
  84. Kaldor JM, Day NE, Clarke EA, van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin’s disease. N Engl J Med. 1990;322:7–13
  85. Bruce LJ, Hancock BW. Immunity in Hodgkin’s disease: status after 10 years’ remission. Br J Cancer. 1990;62:324–325
  86. Hoppe RT, Fuks ZY, Strober S, Kaplan HS. The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation. Cancer. 1977;40:2071–2078
  87. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst. 1995;87:1530–1537
  88. Kawabata I, Takahashi Y, Iwagaki S, Tamaya T. MRI during pregnancy. J Perinat Med. 2003;31:449–458
  89. Levine D. Obstetric MRI. J Magn Reson Imaging. 2006;24:1–15
  90. Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of 18F-FDG in the lactating breast. J Nucl Med. 2001;42:1238–1242
  91. Benveniste H, Fowler JS, Rooney WD, Moller DH, Backus WW, Warner DA, et al. Maternal-fetal in vivo imaging: a combined PET and MRI study. J Nucl Med. 2003;44:1522–1530
  92. Weisz B, Meirow D, Schiff E, Lishner M. Impact and treatment of cancer during pregnancy. Exper Rev Anticancer Ther. 2004;4:889–902
  93. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283–291
  94. Doll DC, Ringenberg QS, Yarbro JW. Management of cancer during pregnancy. Arch Intern Med. 1998;148:2058–2064
  95. Randall T. National registry seeks scarce data on pregnancy outcomes during chemotherapy. JAMA. 1993;269:323
  96. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2:173–177
  97. Weisz B, Schiff E, Lishner M. Cancer in pregnancy: maternal and fetal implications. Hum Reprod Update. 2001;7:384–393
  98. Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Maternal and foetal outcome following Hodgkin’s disease in pregnancy. Br J Cancer. 1992;65:114–117
  99. Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992;152:573–576
  100. Fenig E, Mishaeli M, Kalish Y, Lishner M. Pregnancy and radiation. Cancer Treat Rev. 2001;27:1–7
  101. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6:328–333
  102. Sifakis S, Angelakis E, Vardaki E, Koumantaki Y, Matalliotakis I, Koumantakis E. Erythropoietin in the treatment of iron deficiency anemia during pregnancy. Gynecol Obstet Invest. 2001;51:150–156
  103. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10:412–426
  104. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani RN, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444–450
  105. Tanaka PY, Pessoa VP, Pracchia LF, Buccheri V, Chamone DA, Calore EE. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma. 2007;7:364–368
  106. Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004;125:455–462
  107. Gerard L, Galicier L, Boulanger E, Quint L, Lebrette MG, Mortier E, et al. Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17:81–87
  108. Xicoy B, Ribera RM, Miralles P, Berenguer J, Rubio R, Mahillo B, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. GESIDA group and GELCAB group. Haematologica. 2007;92:191–198
  109. Gastaldi R, Martino P, Gentile G, Picardi V, De Propios MS, Pirillo MF, et al. Hodgkin’s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol. 2002;13:1158–1160
  110. Gaidano G, Carbone A, Dalla-Favera R. Pathogenesis of AIDS-related lymphomas. Am J Pathol. 1998;152:623–630
  111. Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wöhrmann A, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562–1569
  112. Spina M, Gabarre J, Rossi G, Fasan M, Chiantarelli C, Nigra E, et al. Stanford V and concomitant HAART in 59 patients with Hodgkin’s disease and HIV infection. Blood. 2002;100:1984–1988
  113. Spina M, Rossi G, Antinori A, Allione B, Fasan M, Rizzardini G, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients with HD and HIV Infection (HD-HIV). Blood. 2005;106:100a
  114. Spina M, Re A, Vaccher E, Gabarre J, Tirelli U. High international prognostic score predicts a worse outcome for patients with Hodgkin’s disease and HIV infection: results of a prospective study with Stanford V regimen. Ann Oncol. 2003;14:655–656
  115. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–1514
  116. Errante D, Gabarre J, Ridolfo AL, Rossi G, Nosari AM, Gisselbrecht C, et al. Hodgkin’s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSG. Ann Oncol. 1999;10:189–195
  117. Errante D, Tirelli U, Gastaldi R, Milo D, Nosari AM, Rossi G, et al. Combined antineoplastic and anti-retroviral therapy for patients with Hodgkin’s disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian cooperative group on AIDS and tumors (GICAT). Cancer. 1994;73:437–444
  118. Sissolak G, Andrews S, Abayomi A, Jacobs P. Haematopoietic and cardiovascular complications in patients infected with the human immunodeficiency virus Resources Cardiovasc Sci 2009; 17p.
  119. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS society-USA panel. JAMA. 2006;296:827–843
  120. Mellors JW, Munoz A, Giorgi JV, Margolick JW, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946–954
  121. Gallant JE. Should antiretroviral therapy be started earlier?. Curr HIV/AIDS Rep. 2007;4:53–59
  122. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527–533

PII: S1473-0502(10)00009-1

doi: 10.1016/j.transci.2010.01.008

Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 131-139 , April 2010

Article Tools